Cooke & Bieler LP Sells 7,130 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Cooke & Bieler LP reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 419,637 shares of the medical research company's stock after selling 7,130 shares during the quarter. Cooke & Bieler LP owned approximately 0.85% of Charles River Laboratories International worth $63,164,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Rothschild Investment LLC boosted its stake in shares of Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock valued at $26,000 after purchasing an additional 144 shares in the last quarter. HM Payson & Co. bought a new stake in Charles River Laboratories International during the first quarter worth about $31,000. Optiver Holding B.V. bought a new stake in Charles River Laboratories International during the fourth quarter worth about $37,000. GeoWealth Management LLC increased its holdings in shares of Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after buying an additional 190 shares in the last quarter. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in Charles River Laboratories International in the 4th quarter valued at $48,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Stock Down 1.4%

CRL stock traded down $2.15 during mid-day trading on Friday, hitting $154.55. 493,642 shares of the company were exchanged, compared to its average volume of 1,035,730. The firm has a market cap of $7.59 billion, a P/E ratio of -237.77, a P/E/G ratio of 5.31 and a beta of 1.49. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. The firm's 50 day simple moving average is $147.42 and its 200 day simple moving average is $150.81.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The company's quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.27 earnings per share. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Barclays increased their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a report on Thursday, May 8th. Wall Street Zen cut Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Saturday, July 5th. Mizuho lowered their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the company from $190.00 to $170.00 in a research report on Friday, March 21st. Finally, TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target for the company in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $174.54.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the transaction, the executive vice president owned 19,513 shares of the company's stock, valued at $2,837,385.33. The trade was a 2.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).